ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2919

Endothelial Protein C Receptor and Scavenger Receptor Class B Type 1 Negatively Regulate Vascular Inflammation and Are Major Autoantigens in Takayasu Arteritis

Tomoyuki Mutoh1, Tsuyoshi Shirai 1, Tomonori Ishii 2, Yuko Shirota 3, Hideo Harigae 1 and Hiroshi Fujii 1, 1Department of Hematology and Rheumatology, Tohoku University Graduate School of Medicine, Sendai, Japan, 2Tohoku University Hospital, Sendai, Japan, 3Department of Hematology and Rheumatology, Tohoku Medical and Pharmaceutical University, Sendai, Japan

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: autoantigens and autoantibodies, large vessel vasculitis, Takayasu arteritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Wednesday, November 13, 2019

Title: 6W024: Vasculitis – Non-ANCA-Associated & Related Disorders III: Large Vessel Vasculitis Pathogenesis & Imaging (2918–2923)

Session Type: ACR Abstract Session

Session Time: 11:00AM-12:30PM

Background/Purpose: Takayasu arteritis (TAK) is a chronic vasculitis which predominantly affects large vessels. Although anti-endothelial cell antibodies (AECA) had been reported to be involved in vascular inflammation in TAK, their target antigens remained unclear. We had constructed an expression cloning system for specific identification of cell-surface antigens, which we named SARF. The aim of this study was to identify autoantigens expressed on the cell surface and to clarify their pathogenic relevance in TAK.

Methods: AECA activity against human umbilical vein endothelial cells (HUVEC) was measured and prototype AECA for SARF was determined. HUVEC cDNA library was inserted into rat myeloma cells by using retroviral vector, and cells expressing proteins derived from cDNA library of HUVEC were incubated with prototype AECA-IgG. Cells bound to AECA-IgG were sorted by flow cytometry, and inserted cDNA in sorted cells was analyzed to identify autoantigens. The prevalence of autoantibodies identified was measured among collagen diseases, and the clinical characteristics of patients with TAK were evaluated according to the presence of autoantibodies. To examine the pathogenic roles of identified autoantibodies, the activation of HUVEC and differentiation of Th17 cells were evaluated.

Results: We performed SARF by using nine TAK sera, and successfully completed in three patients. Four clones bound to the prototype AECA were established, and endothelial protein C receptor (EPCR) and scavenger receptor class B type 1 (SR-BI) were identified as novel autoantigens in TAK. Among 52 TAK patients, anti-EPCR or anti-SR-BI activity was observed in 18 (34.6%) or 19 (36.5%) patients, respectively, with minimal overlap. Their presence was mostly specific for TAK in collagen diseases. TAK was classified into 3 subtypes based on the activity of autoantibodies. Anti-EPCR positive group showed high prevalence of stroke, ulcerative colitis, and type II lesion. Anti-SR-BI positive group presented higher levels of inflammatory markers, type V lesion, and older age at onset. Aortic regurgitation (AR) was rare in anti-SR-BI group. Double-negative group presented higher rates of surgery for AR. In mechanistic studies, EPCR and SR-BI negatively regulated the upregulation of adhesion molecules on HUVEC upon stimulation. The expression of EPCR was induced upon Th17 differentiation, and its agonist suppressed Th17 differentiation. These functions of autoantigens were inhibited by autoantibodies, which resulted in the activation of endothelial cells and the promotion of Th17 differentiation.

Conclusion: EPCR and SR-BI were identified as novel autoantigens in TAK, and these autoantibodies were observed in 67.3% of TAK patients. These autoantibodies blocked the negative regulatory effects of their targets, and thus would contribute to the chronicity of vascular inflammation in TAK.


Disclosure: T. Mutoh, None; T. Shirai, None; T. Ishii, Abbvie, 8, Asahi, 8, Astellas, 8, Chugai, 8, Daiichi-Sankyo, 8, Eisai, 8, GSK, 2, 5, Janssen, 2, 5, 8, Kasei Pharma, 8, Mitsubishi-Tanabe, 8, Ono, 8, Pfizer, 8, Sanofi, 8, Takeda, 8, Teijin, 8, UCB, 8; Y. Shirota, None; H. Harigae, None; H. Fujii, None.

To cite this abstract in AMA style:

Mutoh T, Shirai T, Ishii T, Shirota Y, Harigae H, Fujii H. Endothelial Protein C Receptor and Scavenger Receptor Class B Type 1 Negatively Regulate Vascular Inflammation and Are Major Autoantigens in Takayasu Arteritis [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/endothelial-protein-c-receptor-and-scavenger-receptor-class-b-type-1-negatively-regulate-vascular-inflammation-and-are-major-autoantigens-in-takayasu-arteritis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/endothelial-protein-c-receptor-and-scavenger-receptor-class-b-type-1-negatively-regulate-vascular-inflammation-and-are-major-autoantigens-in-takayasu-arteritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology